Board Remuneration Review - Cynata Therapeutics

The Brief

To provide benchmarking data to assist the Remuneration Committee to review the remuneration of the Non-executive Directors, Chief Executive Officer, and Chief Operating Officer.

The Methodology

The review provided commentary on Non-executive Director, Chief Executive Officer, and Chief Operating Officer's fixed remuneration and incentives as well as the aggregate Board fees approved by shareholders.

The Comparator Group reviewed against were ASX-listed healthcare & biotechnology companies of a similar market capitalisation.

The report will provide data in relation to the 25th, 50th, and 75th percentiles of the companies reviewed and a recommendation regarding the reasonableness of remuneration.

The Results

The remuneration was completed within two weeks and was tabled at the Annual General Meeting of Cynata Therapeutics to support the recommendations of the Board in relation to the company’s remuneration structure.